Clinical aspects
Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren’s syndrome: data from a nationwide cohort for Sjögren’s syndrome in Korea
Y. Park1, J. Lee2, J.H. Koh3, Y. Sung4, S. Lee5, J.Y. Choe6, S. Shim7, J. Kim8, S.R. Kwon9, H. Kim10, S. Chung11, S.-H. Park12, S. Kwok13
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
- Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea.
- Division of Rheumatology, Daegu Catholic University Medical Centre, Daegu, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Keimyung University Dongsan Medical Centre, Daegu, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
- Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, Republic of Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. seungki73@catholic.ac.kr
CER12486
2019 Vol.37, N°3 ,Suppl.118
PI 0107, PF 0113
Clinical aspects
Free to view
(click on article PDF icon to read the article)
PMID: 31376264 [PubMed]
Received: 07/06/2019
Accepted : 02/07/2019
In Press: 22/07/2019
Published: 28/08/2019
Abstract
OBJECTIVES:
To investigate clinical characteristics of patients with primary Sjögren’s syndrome (SS) who were negative for anti-Ro/SSA antibody but positive for minor salivary gland biopsy (MSGB) compared to patients who presented positivity for anti-Ro/SSA antibody.
METHODS:
The data of 355 patients from the Korean Initiative of primary Sjögren’s Syndrome (KISS), a nationwide prospective cohort for primary SS in Korea, were analysed. All patients fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria. Of these patients, 326 were positive for anti-Ro/SSA antibody and 29 were antibody-negative, although they had positive findings in MSGB. Various clinical features including all kinds of tests for evaluating secretory function, disease-related clinical indices and serological values available in the cohort were compared between the two groups.
RESULTS:
The anti-Ro/SSA-negative group showed less rheumatoid factor positivity (p<0.001), leucopenia (p=0.003), hyper-gammaglobulinaemia (p<0.001), lower serum β2-microglobulin level (p=0.034), more anti-centromere antibody positivity (p<0.001), higher score in dryness domain of EULAR SS patient-reported index (p=0.048) and more positivity for peripheral nervous system domain in EULAR SS disease activity index and loss of teeth in SS disease damage index (p=0.021 and 0.041, respectively) than patients who were positive for anti-Ro/ SSA antibody.
CONCLUSIONS:
Primary SS patients who are negative for anti-Ro/SSA antibody have different clinical characteristics compared to patients who are positive for such antibody in Korea. Therefore, clinicians should consider MSGB in patients with suspicious symptoms who are anti-Ro/SSA-negative.
